Sex-Related Gap in the Use of Disease-Modifying Therapies in Multiple Sclerosis.

Date publication

août 2025

Journal

Neurology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme

Tous les auteurs :
Gavoille A, Leray E, Marignier R, Rollot F, Casey R, Mathey G, Michel L, De Seze J, Ciron J, Ruet A, Maillart E, Labauge P, Zephir H, Laplaud DA, Papeix C, Defer G, Moreau T, Berger E, Dubessy AL, Clavelou P, Thouvenot E, Heinzlef O, Pelletier J, Al Khedr A, Casez O, Bourre B, Wahab A, Magy L, Camdessanche JP, Doghri I, Moulin S, Labeyrie C, Hankiewicz K, Dos Santos A, Pottier C, Manchon E, Tchikviladze M, Lebrun-Frenay C, Vukusic S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40737571

Résumé

In women with multiple sclerosis (MS), the therapeutic strategy may be influenced by the anticipation of future pregnancies, leading to underexposure to disease-modifying therapies (DMTs) and highly effective DMTs (HEDMTs) compared with men. We aimed to evaluate potential therapeutic inertia in women with MS and explore its causes.

Mots clés

Humans, Female, Adult, Male, Retrospective Studies, Multiple Sclerosis, Relapsing-Remitting, drug therapy, Sex Factors, Immunologic Factors, therapeutic use, Young Adult, Pregnancy, Adolescent, Glatiramer Acetate, therapeutic use, Cohort Studies, Natalizumab, therapeutic use, Toluidines, therapeutic use, Crotonates, therapeutic use, Hydroxybutyrates, Nitriles

Référence

Neurology. 2025 08 26;105(4):e213907